HOLYOKE
Cancer Incidence by Sex, 1993 - 1997
Expected and Observed Case Counts, with Standardized Incidence Ratios

| | Exp | <u>Obs</u> | <u>SIR</u> | | Exp | <u>Obs</u> | SIR |
|---|-------------|------------|------------|-------------------------|--------|------------|--------|
| Bladder, Urinary | | | | Melanoma of Skin | | | |
| Male | 26.24 | 22 | 84 | Male | 14.03 | 10 | 71 |
| Female | 11.58 | 15 | 130 | Female | 12.36 | 11 | 89 |
| Total | 37.82 | 37 | 98 | Total | 26.39 | 21 | 80 |
| Brain and Other Central Nervous System | | | | Multiple Myeloma | | | |
| Male | 7.69 | 9 | 117 | Male | 4.71 | 10 | 212 #+ |
| Female | 7.52 | 6 | 80 | Female | 4.96 | 6 | 121 |
| Total | 15.21 | 15 | 99 | Total | 9.66 | 16 | 166 |
| <u>Breast</u> | | | | Non-Hodgkin's Lymphoma | | | |
| Male | 1.63 | 1 | NC* | Male | 19.12 | 13 | 68 |
| Female | 158.47 | 137 | 86 | Female | 20.17 | 23 | 114 |
| Total | 160.10 | 138 | 86 | Total | 39.29 | 36 | 92 |
| Cervix Uteri | | | | Oral Cavity and Pharynx | | | |
| | | | | Male | 14.89 | 21 | 141 |
| Female | 9.50 | 17 | 179 #+ | Female | 8.67 | 10 | 115 |
| | | | | Total | 23.56 | 31 | 132 |
| Colon / Rectur | <u>n</u> | | | Ovary | | | |
| Male | 65.44 | 73 | 112 | | | | |
| Female | 75.29 | 69 | 92 | Female | 18.79 | 23 | 122 |
| Total | 140.73 | 142 | 101 | | | | |
| Esophagus | | | | Pancreas | | | |
| Male | 8.69 | 10 | 115 | Male | 9.41 | 11 | 117 |
| Female | 3.85 | 9 | 234 #+ | Female | 12.01 | 15 | 125 |
| Total | 12.54 | 19 | 151 | Total | 21.42 | 26 | 121 |
| Hodgkin's Dis | <u>ease</u> | | | Prostate | | | |
| Male | 3.57 | 3 | NC* | Male | 151.72 | 121 | 80 #- |
| Female | 3.16 | 5 | 158 | | | | |
| Total | 6.73 | 8 | 119 | | | | |
| Kidney and Ro | enal Pelvis | | | Stomach | | | |
| Male | 13.73 | 13 | 95 | Male | 11.05 | 10 | 90 |
| Female | 9.52 | 6 | 63 | Female | 8.21 | 2 | NC* |
| Total | 23.26 | 19 | 82 | Total | 19.26 | 12 | 62 |
| Larynx | | | | Testis | | | |
| Male | 8.07 | 13 | 161 | Male | 4.71 | 2 | NC* |

| Female | 2.46 | 2 | NC* | | | | |
|--|--------|-----|-----|--------------------------------------|---------|------|--------|
| Total | 10.53 | 15 | 142 | | | | |
| Leukemia | | | | Thyroid | | | |
| Male | 10.88 | 7 | 64 | Male | 2.55 | 0 | NC* |
| Female | 9.51 | 11 | 116 | Female | 7.63 | 14 | 184 #+ |
| Total | 20.40 | 18 | 88 | Total | 10.18 | 14 | 138 |
| Liver and Intrahepatic Bile Ducts | | | | Uteri, Corpus and Uterus, NOS | | | |
| Male | 4.79 | 4 | NC* | | | | |
| Female | 2.46 | 2 | NC* | Female | 30.26 | 48 | 159 ~+ |
| Total | 7.25 | 6 | 83 | | | | |
| Lung and Bronchus | | | | All Sites / Types | | | |
| Male | 79.11 | 90 | 114 | Male | 496.74 | 471 | 95 |
| Female | 66.09 | 58 | 88 | Female | 523.62 | 533 | 102 |
| Total | 145.20 | 148 | 102 | Total | 1020.36 | 1004 | 98 |

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels